Table of Contents

• Trial overview
• Who can take part
• Study design and treatment
• What the study measures
• Trial phase and status
• Why this research matters

Trial overview

The available trial data describe one interventional study of ROPINIROLE in healthy volunteers.^[1] The study is designed to test whether a single oral dose changes metacognition and resting-state functional brain connectivity.^[1]

The trial title and summary show that the main focus is not a disease treatment study, but a mechanistic study of how ROPINIROLE may affect self-monitoring and brain network activity in people without a known illness.^[1]

Who can take part

The target population is healthy adults, described in the trial as healthy volunteers.^[1] The study does not list a disease group, so it is aimed at understanding the drug’s effect in people without the condition being studied.^[1]

The enrollment goal is 20 participants, which means this is a small study.^[1] Small studies like this are often used to explore a question before larger studies are done.^[1]

Study design and treatment

This is an interventional trial, meaning the researchers give a study treatment and then measure the effect.^[1] The intervention includes placebo and ROPINIROLE 1 mg given by mouth as a single dose.^[1]

Placebo is a look-alike treatment with no active study drug, and it is used to compare results fairly.^[1] The trial compares ROPINIROLE with placebo to see whether the drug changes confidence, accuracy, and brain connectivity.^[1]

What the study measures

The primary endpoint is the within-participant change in metacognitive efficiency, also called the M-ratio, under ROPINIROLE versus placebo.^[1] This is measured from confidence ratings during cognitive testing and uses a signal-detection-theoretic framework, which helps separate self-judgment from task performance.^[1]

The study uses a modified version of the Rey Auditory-Verbal Learning Test, which is a memory task that asks people to learn and recall words.^[1] Researchers use trial-by-trial accuracy and confidence ratings to see whether confidence matches actual performance.^[1]

The summary also says the study will look at metacognitive bias, meaning the gap between confidence and actual performance, and Goodman–Kruskal Gamma correlation, which shows how well confidence separates correct answers from errors.^[1] The brief summary states that the researchers want to know whether ROPINIROLE changes confidence without changing basic cognitive performance.^[1]

Trial phase and status

The trial is listed as Phase 4 and has the status Authorised.^[1] In the trial record, Phase 4 is linked with a product that already has marketing authorization and has been shown to be safe in humans.^[1]

Even though the product is already authorised, this study is still important because it asks a new research question about brain function and self-evaluation in healthy people.^[1]

Why this research matters

The trial summary explains that the researchers want to understand how dopaminergic stimulation may affect insight into one’s own performance.^[1] In simple terms, they are studying whether ROPINIROLE can make people more or less overconfident about their answers.^[1]

The study is also meant to help explain brain systems involved in self-awareness and unawareness of neurological disturbances, which is sometimes called anosognosia.^[1] The data suggest that findings from healthy volunteers may help guide future research on people who have problems with insight into their condition.^[1]